JAC Advance Access first published online on October 13, 2007
This version published online on October 19, 2007
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkm385
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Systematic review |
Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis
1 Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece 2 Department of Medicine, Henry Dunant Hospital, Athens, Greece 3 Department of Medicine, Tufts University School of Medicine, Boston, MA, USA
Received 2 August 2007; returned 26 August 2007; revised 12 September 2007; accepted 13 September 2007
* Correspondence address. Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece. Tel: +30-694-611-0000; Fax: +30-210-683-9605; E-mail: m.falagas{at}aibs.gr
Background: Aerosolized antibiotics are a widely recognized treatment for patients with cystic fibrosis (CF). We sought to clarify their role in the treatment of non-CF patients with nosocomial pneumonia by performing a meta-analysis of randomized controlled trials (RCTs) that compared administration of antimicrobials via the respiratory tract (with or without concurrent usage of systemic antibiotics) with control treatment.
Methods: An extensive search of PubMed, Scopus, Cochrane Central Register of Controlled Trials, Current Contents and bibliographies from retrieved publications was made.
Results: Five RCTs were included in the meta-analysis. Administration of antimicrobials via respiratory tract (either inhaled or endotracheally instilled) as opposed to control was associated with better treatment success in intention-to-treat [fixed effect model: odds ratio (OR) = 2.39, 95% confidence interval (CI) 1.29–4.44; random effects model: OR = 2.75, 95% CI 1.06–7.17] and in clinically evaluable patients (fixed effect model: OR = 3.14, 95% CI 1.48–6.70; random effects model: OR = 3.07, 95% CI 1.15–8.19). There were no statistically significant differences between therapeutic regimens regarding all-cause mortality (fixed effect model: OR = 0.84, 95% CI 0.43–1.64; random effects model: OR = 0.71, 95% CI 0.27–1.88), microbiological success (fixed effect model: OR = 2.06, 95% CI 0.91–4.68; random effects model: OR = 2.23, 95% CI 0.64–7.71) and toxicity (fixed effect model: OR = 0.34, 95% CI 0.04–2.53; random effects model: OR = 0.36, 95% CI 0.04–3.16).
Conclusions: The limited available evidence seems not to preclude a benefit from the administration of antimicrobial agents via the respiratory tract for treating nosocomial pneumonia.
Key Words: ICU-acquired pneumonia , healthcare-associated pneumonia , ventilator-associated pneumonia , respiratory tract infections
The originally published version of this paper was incorrect. There was an error in the abstract.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. A. El Solh and A. Alhajhusain Update on the treatment of Pseudomonas aeruginosa pneumonia J. Antimicrob. Chemother., August 1, 2009; 64(2): 229 - 238. [Abstract] [Full Text] [PDF]
|
|